The DOI matches its Crossref record; 101 of the 101 references it cites were found in a registry or an index.
LAG 3 (CD 223) as a cancer immunotherapy target
Open accessAbstract
Summary: Despite the impressive impact of CTLA 4 and PD 1‐PDL 1‐targeted cancer immunotherapy, a large proportion of patients with many tumor types fail to respond. Consequently, the focus has shifted to targeting alternative inhibitory receptors (IR s) and suppressive mechanisms within the tumor microenvironment. Lymphocyte activation gene‐3 (LAG 3) (CD 223) is the third IR to be targeted in the clinic, consequently garnering considerable interest and scrutiny. LAG 3 upregulation is required to control overt activation and prevent the onset of autoimmunity. However, persistent antigen exposure in the tumor microenvironment results in sustained LAG 3 expression, contributing to a state of exhaustion manifest in impaired proliferation and cytokine production. The exact signaling mechanisms downstream of LAG 3 and interplay with other IR s remain largely unknown. However, the striking synergy between LAG 3 and PD 1 observed in multiple settings, coupled with the contrasting intracellular cytoplasmic domain of LAG 3 as compared with other IR s, highlights the potential uniqueness of LAG 3. There are now four LAG 3‐targeted therapies in the clinic with many more in preclinical development, emphasizing the broad interest in this IR. Given the translational relevance of LAG 3 and the heightened interest in the impact of dual LAG 3/PD 1 targeting in the clinic, the outcome of these trials could serve as a nexus; significantly increasing or dampening enthusiasm for subsequent targets in the cancer immunotherapeutic pipeline.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationSafety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 1×
“As a result, the number of possible immunotherapy regimens has grown exponentially, giving rise to the rationale that synergistic combinations should yield significant clinical improvement compared with current monotherapies (13).”
BackgroundSelf-citationCuriel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781
Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection
Wherry, E. J., Ha, S.-J., Kaech, S. M., Haining, W. N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J. N., Barber, D. L., & Ahmed, R. (2007) · Immunity · doi:10.1016/j.immuni.2007.09.006 · Cited by 2,103
Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation
Anderson, A. C., Joller, N., & Kuchroo, V. K. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.001 · Cited by 2,096
Blackburn, S. D., Shin, H., Haining, W. N., Zou, T., Workman, C. J., Polley, A., Betts, M. R., Freeman, G. J., Vignali, D. A. A., & Wherry, E. J. (2009) · Nature Immunology · doi:10.1038/ni.1679 · Cited by 2,062
Self-citationCouzin-Frankel, J. (2013) · Science · doi:10.1126/science.342.6165.1432 · Cited by 2,051
Plasmacytoid dendritic cells in immunity
Colonna, M., Trinchieri, G., & Liu, Y.-J. (2004) · Nature Immunology · doi:10.1038/ni1141 · Cited by 1,678
Woo, S.-R., Turnis, M. E., Goldberg, M. V., Bankoti, J., Selby, M., Nirschl, C. J., Bettini, M. L., Gravano, D. M., Vogel, P., Liu, C. L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1620 · Cited by 1,647
Self-citationLlosa, N. J., Cruise, M., Tam, A., Wicks, E. C., Hechenbleikner, E. M., Taube, J. M., Blosser, R. L., Fan, H., Wang, H., Luber, B. S., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0863 · Cited by 1,487
Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection
Wherry, E. J., Ha, S.-J., Kaech, S. M., Haining, W. N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J. N., Barber, D. L., & Ahmed, R. (2007) · Immunity · doi:10.1016/j.immuni.2007.11.006 · Cited by 1,354
Role of LAG-3 in Regulatory T Cells
Huang, C.-T., Workman, C. J., Flies, D., Pan, X., Marson, A. L., Zhou, G., Hipkiss, E. L., Ravi, S., Kowalski, J., Levitsky, H. I., et al. (2004) · Immunity · doi:10.1016/j.immuni.2004.08.010 · Cited by 1,325
Self-citationChemnitz, J. M., Parry, R. V., Nichols, K. E., June, C. H., & Riley, J. L. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.2.945 · Cited by 1,246
Galectin-3: An open-ended story
Dumic, J., Dabelic, S., & Flögel, M. (2006) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2005.12.020 · Cited by 1,169
Redefining Chronic Viral Infection
Virgin, H. W., Wherry, E. J., & Ahmed, R. (2009) · Cell · doi:10.1016/j.cell.2009.06.036 · Cited by 1,031
Regulatory T cells in tumor immunity
Nishikawa, H., & Sakaguchi, S. (2010) · International Journal of Cancer · doi:10.1002/ijc.25429 · Cited by 944
LAG-3, a novel lymphocyte activation gene closely related to CD4.
Triebel, F., Jitsukawa, S., Baixeras, E., Roman-Roman, S., Genevee, C., Viegas-Pequignot, E., & Hercend, T. (1990) · The Journal of experimental medicine · doi:10.1084/jem.171.5.1393 · Cited by 925
Coinhibitory Pathways in Immunotherapy for Cancer
Baumeister, S. H., Freeman, G. J., Dranoff, G., & Sharpe, A. H. (2016) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112049 · Cited by 910
Matsuzaki, J., Gnjatic, S., Mhawech-Fauceglia, P., Beck, A., Miller, A., Tsuji, T., Eppolito, C., Qian, F., Lele, S., Shrikant, P., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1003345107 · Cited by 859
Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients
Baitsch, L., Baumgaertner, P., Devêvre, E., Raghav, S. K., Legat, A., Barba, L., Wieckowski, S., Bouzourene, H., Deplancke, B., Romero, P., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46102 · Cited by 845
Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells
Gagliani, N., Magnani, C. F., Huber, S., Gianolini, M. E., Pala, M., Licona-Limon, P., Guo, B., Herbert, D. R., Bulfone, A., Trentini, F., et al. (2013) · Nature Medicine · doi:10.1038/nm.3179 · Cited by 793
Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3
Mao, X., Ou, M. T., Karuppagounder, S. S., Kam, T.-I., Yin, X., Xiong, Y., Ge, P., Umanah, G. E., Brahmachari, S., Shin, J.-H., et al. (2016) · Science · doi:10.1126/science.aah3374 · Cited by 690
Self-citationLiang, B., Workman, C., Lee, J., Chew, C., Dale, B. M., Colonna, L., Flores, M., Li, N., Schweighoffer, E., Greenberg, S., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.9.5916 · Cited by 566
Self-citationGrosso, J. F., Kelleher, C. C., Harris, T. J., Maris, C. H., Hipkiss, E. L., De Marzo, A., Anders, R., Netto, G., Getnet, D., Bruno, T. C., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31184 · Cited by 547
Self-citationKouo, T., Huang, L., Pucsek, A. B., Cao, M., Solt, S., Armstrong, T., & Jaffee, E. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0150 · Cited by 531
Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
Gettinger, S., Rizvi, N. A., Chow, L. Q., Borghaei, H., Brahmer, J., Ready, N., Gerber, D. E., Shepherd, F. A., Antonia, S., Goldman, J. W., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.9929 · Cited by 501
Reversing T-cell Dysfunction and Exhaustion in Cancer
Zarour, H. M. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1849 · Cited by 462
Baixeras, E., Huard, B., Miossec, C., Jitsukawa, S., Martin, M., Hercend, T., Auffray, C., Triebel, F., & Piatier-Tonneau, D. (1992) · The Journal of experimental medicine · doi:10.1084/jem.176.2.327 · Cited by 397
Huard, B., Prigent, P., Tournier, M., Bruniquel, D., & Triebel, F. (1995) · European Journal of Immunology · doi:10.1002/eji.1830250949 · Cited by 391
Cutting Edge: Molecular Analysis of the Negative Regulatory Function of Lymphocyte Activation Gene-3
Workman, C. J., Dugger, K. J., & Vignali, D. A. A. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.10.5392 · Cited by 389
Self-citationXu, F., Liu, J., Liu, D., Liu, B., Wang, M., Hu, Z., Du, X., Tang, L., & He, F. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2690 · Cited by 373
Workman, C. J., Cauley, L. S., Kim, I.-J., Blackman, M. A., Woodland, D. L., & Vignali, D. A. A. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.9.5450 · Cited by 351
Self-citationCamisaschi, C., Casati, C., Rini, F., Perego, M., De Filippo, A., Triebel, F., Parmiani, G., Belli, F., Rivoltini, L., & Castelli, C. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903879 · Cited by 350
CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers
Huang, B., Lei, Z., Zhao, J., Gong, W., Liu, J., Chen, Z., Liu, Y., Li, D., Yuan, Y., Zhang, G.-M., et al. (2007) · Cancer Letters · doi:10.1016/j.canlet.2006.12.012 · Cited by 349
Negative Regulation of T Cell Homeostasis by Lymphocyte Activation Gene-3 (CD223)
Workman, C. J., & Vignali, D. A. A. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.2.688 · Cited by 332
Self-citationThe CD4‐related molecule, LAG‐3 (CD223), regulates the expansion of activated T cells
Workman, C. J., & Vignali, D. A. A. (2003) · European Journal of Immunology · doi:10.1002/eji.200323382 · Cited by 319
Self-citationLAG-3 Regulates Plasmacytoid Dendritic Cell Homeostasis
Workman, C. J., Wang, Y., El Kasmi, K. C., Pardoll, D. M., Murray, P. J., Drake, C. G., & Vignali, D. A. A. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0800185 · Cited by 316
Self-citationCharacterization of the major histocompatibility complex class II binding site on LAG-3 protein
Huard, B., Mastrangeli, R., Prigent, P., Bruniquel, D., Donini, S., El-Tayar, N., Maigret, B., Dréano, M., & Triebel, F. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.11.5744 · Cited by 308
Huang, R.-Y., Eppolito, C., Lele, S., Shrikant, P., Matsuzaki, J., & Odunsi, K. (2015) · Oncotarget · doi:10.18632/oncotarget.4751 · Cited by 308
Jie, H.-B., Gildener-Leapman, N., Li, J., Srivastava, R. M., Gibson, S. P., Whiteside, T. L., & Ferris, R. L. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.645 · Cited by 286
Metalloproteases regulate T‐cell proliferation and effector function via LAG‐3
Li, N., Wang, Y., Forbes, K., Vignali, K. M., Heale, B. S., Saftig, P., Hartmann, D., Black, R. A., Rossi, J. J., Blobel, C. P., et al. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601520 · Cited by 282
Self-citationFunctionally Distinct LAG-3 and PD-1 Subsets on Activated and Chronically Stimulated CD8 T Cells
Grosso, J. F., Goldberg, M. V., Getnet, D., Bruno, T. C., Yen, H.-R., Pyle, K. J., Hipkiss, E., Vignali, D. A. A., Pardoll, D. M., & Drake, C. G. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0804211 · Cited by 272
Self-citationExpression of lymphocyte activation gene 3 (LAG-3) on B cells is induced by T cells
Kisielow, M., Kisielow, J., Capoferri-Sollami, G., & Karjalainen, K. (2005) · European Journal of Immunology · doi:10.1002/eji.200526090 · Cited by 271
Wang, J.-H., Meijers, R., Xiong, Y., Liu, J.-H., Sakihama, T., Zhang, R., Joachimiak, A., & Reinherz, E. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191124098 · Cited by 257
MHC Class II Engagement by Its Ligand LAG-3 (CD223) Contributes to Melanoma Resistance to Apoptosis
Hemon, P., Jean-Louis, F., Ramgolam, K., Brignone, C., Viguier, M., Bachelez, H., Triebel, F., Charron, D., Aoudjit, F., Al-Daccak, R., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1002050 · Cited by 252
Taube, J. M., Young, G. D., McMiller, T. L., Chen, S., Salas, J. T., Pritchard, T. S., Xu, H., Meeker, A. K., Fan, J., Cheadle, C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0244 · Cited by 246
Huard, B., Tournier, M., Hercend, T., Triebel, F., & Faure, F. (1994) · European Journal of Immunology · doi:10.1002/eji.1830241246 · Cited by 241
Active tuberculosis in Africa is associated with reduced Th1 and increased Th2 activity in vivo
Lienhardt, C., Azzurri, A., Amedei, A., Fielding, K., Sillah, J., Sow, O. Y., Bah, B., Benagiano, M., Diallo, A., Manetti, R., et al. (2002) · European Journal of Immunology · doi:10.1002/1521-4141(200206)32:6<1605::aid-immu1605>3.0.co;2-6 · Cited by 227
Brignone, C., Escudier, B., Grygar, C., Marcu, M., & Triebel, F. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0068 · Cited by 226
Restoring Immune Function of Tumor-Specific CD4+ T Cells during Recurrence of Melanoma
Goding, S. R., Wilson, K. A., Xie, Y., Harris, K. M., Baxi, A., Akpinarli, A., Fulton, A., Tamada, K., Strome, S. E., & Antony, P. A. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300271 · Cited by 206
Maçon‐Lemaître, L., & Triebel, F. (2005) · Immunology · doi:10.1111/j.1365-2567.2005.02145.x · Cited by 192
Maturation and Activation of Dendritic Cells Induced by Lymphocyte Activation Gene-3 (CD223)
Andreae, S., Piras, F., Burdin, N., & Triebel, F. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.8.3874 · Cited by 187
Lymphocyte Activation Gene 3 (LAG-3) Modulates the Ability of CD4 T-cells to Be Suppressed In Vivo
Durham, N. M., Nirschl, C. J., Jackson, C. M., Elias, J., Kochel, C. M., Anders, R. A., & Drake, C. G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109080 · Cited by 178
Self-citationTriebel, F., Hacene, K., & Pichon, M.-F. (2006) · Cancer Letters · doi:10.1016/j.canlet.2005.04.015 · Cited by 176
Inhibitory receptors as targets for cancer immunotherapy
Turnis, M. E., Andrews, L. P., & Vignali, D. A. A. (2015) · European Journal of Immunology · doi:10.1002/eji.201344413 · Cited by 175
Self-citationCutting Edge: Accelerated Autoimmune Diabetes in the Absence of LAG-3
Bettini, M., Szymczak-Workman, A. L., Forbes, K., Castellaw, A. H., Selby, M., Pan, X., Drake, C. G., Korman, A. J., & Vignali, D. A. A. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100714 · Cited by 169
Self-citationAttributes of γδ intraepithelial lymphocytes as suggested by their transcriptional profile
Fahrer, A. M., Konigshofer, Y., Kerr, E. M., Ghandour, G., Mack, D. H., Davis, M. M., & Chien, Y.-H. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171320798 · Cited by 168
Characterization of a Novel C-type Lectin-like Gene, LSECtin
Liu, W., Tang, L., Zhang, G., Wei, H., Cui, Y., Guo, L., Gou, Z., Chen, X., Jiang, D., Zhu, Y., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311227200 · Cited by 166
Denning, T. L., Granger, S., Mucida, D., Graddy, R., Leclercq, G., Zhang, W., Honey, K., Rasmussen, J. P., Cheroutre, H., Rudensky, A. Y., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.7.4230 · Cited by 160
Li, F., Zhang, Y., Jin, G., Yao, L., & Wu, D. (2012) · Immunology Letters · doi:10.1016/j.imlet.2012.12.004 · Cited by 147
Scurr, M. J., Ladell, K., Besneux, M., Christian, A. D., Hockey, T., Smart, K., Bridgeman, H. M., Hargest, R., Phillips, S. M., Davies, M. M., et al. (2013) · Mucosal Immunology · doi:10.1038/mi.2013.62 · Cited by 142
On the role of the inhibitory receptor LAG-3 in acute and chronic LCMV infection
Richter, K., Agnellini, P., & Oxenius, A. (2009) · International Immunology · doi:10.1093/intimm/dxp107 · Cited by 141
Biochemical Analysis of the Regulatory T Cell Protein Lymphocyte Activation Gene-3 (LAG-3; CD223)
Li, N., Workman, C. J., Martin, S., & Vignali, D. A. A. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.11.6806 · Cited by 138
Self-citationThe effect of immune microenvironment on the progression and prognosis of colorectal cancer
Chen, J., & Chen, Z. (2014) · Medical Oncology · doi:10.1007/s12032-014-0082-9 · Cited by 137
Donia, M., Andersen, R. S., Kjeldsen, J. W., Fagone, P., Ahmad, S. M., Nicoletti, F., Andersen, M. H., Straten, P. T., & Svane, I. M. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2956 · Cited by 131
Jing, W., Gershan, J. A., Weber, J. J., Tlomak, D., McOlash, L., Sabatos-Peyton, C. A., & Johnson, B. D. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-014-0043-z · Cited by 130
Avice, M.-N., Sarfati, M., Triebel, F., Delespesse, G., & Demeure, C. E. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.5.2748 · Cited by 130
Avice, M.-N., Sarfati, M., Triebel, F., et al. (1999) · PubMed · Cited by 114
MHC antigens in human melanomas.
Dj, R., Mattijssen, V., Broecker, E.-B., & Ferrone, S. (1991) · PubMed · Cited by 111
Bae, J., Lee, S. J., Park, C., Lee, Y. S., & Chun, T. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1401025 · Cited by 104
Camisaschi, C., Filippo, A. D., Beretta, V., Vergani, B., Villa, A., Vergani, E., Santinami, M., Cabras, A. D., Arienti, F., Triebel, F., et al. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.29 · Cited by 104
Clayton, K., Douglas-Vail, M. B., Rahman, A. K. M. N.-U., Medcalf, K. E., Xie, I. Y., Chew, G. M., Tandon, R., Lanteri, M. C., Norris, P. J., Deeks, S. G., et al. (2015) · Journal of Virology · doi:10.1128/jvi.00006-15 · Cited by 102
Wang‐Gillam, A., Plambeck-Suess, S. M., Goedegebuure, P. S., Simon, P. O., Mitchem, J. B., Hornick, J. R., Sorscher, S. M., Picus, J., Suresh, R., Lockhart, A. C., et al. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9866-y · Cited by 97
Iouzalen, N., Andreae, S., Hannier, S., & Triebel, F. (2001) · European Journal of Immunology · doi:10.1002/1521-4141(2001010)31:10<2885::aid-immu2885>3.0.co;2-2 · Cited by 96
Legat, A., Hajjami, H. M.-E., Baumgaertner, P., Cagnon, L., Maillard, S. A., Geldhof, C., Iancu, E. M., Lebon, L., Guillaume, P., Dojcinovic, D., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1212 · Cited by 93
Using gene co-expression network analysis to predict biomarkers for chronic lymphocytic leukemia
Zhang, J., Xiang, Y., Ding, L., Circle, K. C., Borlawsky, T. B., Özer, H. G., Jin, R., Payne, P., & Huang, K. (2010) · BMC Bioinformatics · doi:10.1186/1471-2105-11-s9-s5 · Cited by 92
Mammalian cell display for the discovery and optimization of antibody therapeutics
Bowers, P. M., Horlick, R. A., Kehry, M. R., Neben, T. Y., Tomlinson, G. L., Altobell, L., Zhang, X., Macomber, J. L., Krapf, I. P., Wu, B. F., et al. (2013) · Methods · doi:10.1016/j.ymeth.2013.06.010 · Cited by 88
Differential subcellular localization of the regulatory T‐cell protein LAG‐3 and the coreceptor CD4
Woo, S., Li, N., Bruno, T. C., Forbes, K., Brown, S. A., Workman, C. J., Drake, C. G., & Vignali, D. A. A. (2010) · European Journal of Immunology · doi:10.1002/eji.200939874 · Cited by 87
Self-citationRomano, E., Michielin, O. A., Voelter, V., Laurent, J., Bichat, H., Stravodimou, A., Romero, P. J., Speiser, D. E., Triebel, F., Leyvraz, S., et al. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-97 · Cited by 84
Tr1-Like T Cells – An Enigmatic Regulatory T Cell Lineage
White, A. M., & Wraith, D. C. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00355 · Cited by 83
Wei, T., Zhang, J., Qin, Y., Wu, Y. C., Zhu, L. X., Lu, L., Tang, G., & Shen, Q. (2015) · Europe PMC (PubMed Central) · Cited by 75
Hannier, S., & Triebel, F. (1999) · International Immunology · doi:10.1093/intimm/11.11.1745 · Cited by 72
Liu, L., Lam, C. K., Long, V., Widjaja, L., Yang, Y., Li, H., Jin, L. X., Burke, S., Gorlatov, S. N., Brown, J. G., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0666 · Cited by 72
Brignone, C., Grygar, C., Marcu, M., Schäkel, K., & Triebel, F. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.6.4202 · Cited by 70
Moebius, U., Pallai, P. V., Harrison, S. C., & Reinherz, E. L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.17.8259 · Cited by 70
LAG‐3 (CD223) reduces macrophage and dendritic cell differentiation from monocyte precursors
Buisson, S., & Triebel, F. (2005) · Immunology · doi:10.1111/j.1365-2567.2004.02087.x · Cited by 65
Mouse CD4 binds MHC class II with extremely low affinity
Weber, S., & Karjalainen, K. (1993) · International Immunology · doi:10.1093/intimm/5.6.695 · Cited by 63
Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model
Waugh, K. A., Leach, S. M., Moore, B. L., Bruno, T. C., Buhrman, J. D., & Slansky, J. E. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1600589 · Cited by 61
Lymphocyte Activation Gene-3 (LAG-3) Negatively Regulates Environmentally-Induced Autoimmunity
Jha, V., Workman, C. J., McGaha, T. L., Li, L., Vas, J., Vignali, D. A. A., & Monestier, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104484 · Cited by 52
Self-citationBuisson, S., & Triebel, F. (2003) · Vaccine · doi:10.1016/s0264-410x(02)00533-9 · Cited by 52
Gravitz, L. (2013) · Nature · doi:10.1038/504s1a · Cited by 47
Juno, J. A., Stalker, A., Waruk, J. L. M., Oyugi, J. O., Kimani, M., Plummer, F. A., Kimani, J., & Fowke, K. R. (2015) · Retrovirology · doi:10.1186/s12977-015-0142-z · Cited by 44
Byun, H., Jung, W., Lee, D., Kim, S., Kim, S. J., Park, C., Chung, H. Y., & Chun, T. (2006) · Cell Biology International · doi:10.1016/j.cellbi.2006.11.002 · Cited by 42
Cloning of Murine LAG-3 by Magnetic Bead Bound Homologous Probes and PCR (GENE-CAPTURE PCR)
Mastrangeli, R., Micangeli, E., & Donini, S. (1996) · Analytical Biochemistry · doi:10.1006/abio.1996.0382 · Cited by 42
Modulation of Redox Balance Leaves Murine Diabetogenic TH1 T Cells “LAG-3-ing” Behind
Delmastro-Greenwood, M. M., Styche, A. J., Trucco, M., Workman, C. J., Vignali, D. A. A., & Piganelli, J. D. (2012) · Diabetes · doi:10.2337/db11-1591 · Cited by 41
Self-citationFoy, S. P., Sennino, B., Cruz, T. D., Cote, J. J., Gordon, E. J., Kemp, F., Xavier, V., Franzusoff, A., Rountree, R. B., & Mandl, S. J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0150084 · Cited by 38
Phenotypic analysis of the murine CD4-related glycoprotein, CD223 (LAG-3)
(2002) · doi:10.1002/1521-4141(200208)32:8<2255::aid-immu2255>3.0.co;2-a
Cited by
Therapeutic Targeting of the Tumor Microenvironment
Bejarano, L., Jordāo, M. J. C., & Joyce, J. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1808 · Cited by 1,653
Immune checkpoint signaling and cancer immunotherapy
He, X., & Xu, C. (2020) · Cell Research · doi:10.1038/s41422-020-0343-4 · Cited by 1,371
Advances in immunotherapy for hepatocellular carcinoma
Sangro, B., Sarobe, P., Hervás-Stubbs, S., & Melero, I. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00438-0 · Cited by 1,306
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
Qin, S., Xu, L., Yi, M., Yu, S., Wu, K., & Luo, S. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1091-2 · Cited by 1,145
Keren, L., Bosse, M., Marquez, D., Angoshtari, R., Jain, S., Varma, S., Yang, S.-R., Kurian, A., Van Valen, D., West, R., et al. (2018) · Cell · doi:10.1016/j.cell.2018.08.039 · Cited by 1,183
Metadata
- Authors
- Andrews, L. P., Marciscano, A. E., Drake, C. G., & Vignali, D. A. A.
- Venue
- Immunological Reviews
- Publisher
- Wiley
- Published
- 2017-03
- Volume
- 276
- Issue
- 1
- Pages
- 80-96
- ISSN
- 0105-2896 (ISSN-L)
- 1600-065X
- OpenAlex
- W2593111137
- Cited by
- 956
- References
- 101
- FWCI
- 7.36
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.